Cargando…

FNDC5 Causes Resistance to Sorafenib by Activating the PI3K/Akt/Nrf2 Pathway in Hepatocellular Carcinoma Cells

In this study, we aimed to reveal the resistance mechanism of hepatocellular carcinoma (HCC) cells to sorafenib by exploring the effect of FNDC5 on sorafenib-induced ferroptosis in HCC cells. We compared the expression level of FNDC5 between sorafenib-resistant and sorafenib-sensitive HCC cell lines...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Huayuan, Zhao, Lei, Wang, Mengya, Yang, Kexin, Jin, Zhipeng, Zhao, Chengjian, Shi, Guangjun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8980859/ https://www.ncbi.nlm.nih.gov/pubmed/35392237 http://dx.doi.org/10.3389/fonc.2022.852095

Ejemplares similares

Tanshinone IIA affects the malignant growth of Cholangiocarcinoma cells by inhibiting the PI3K-Akt-mTOR pathway
por: Liu, Huayuan, et al.
Publicado: (2021)

FNDC4 acts as an extracellular factor to promote the invasiveness of hepatocellular carcinoma partly via the PI3K/Akt signalling pathway
por: Wang, Baolin, et al.
Publicado: (2021)

TIPE Regulates DcR3 Expression and Function by Activating the PI3K/AKT Signaling Pathway in CRC
por: Zhong, Mengya, et al.
Publicado: (2021)

LY294002 Is a Promising Inhibitor to Overcome Sorafenib Resistance in FLT3-ITD Mutant AML Cells by Interfering With PI3K/Akt Signaling Pathway
por: Huang, Amin, et al.
Publicado: (2021)

Knockdown of AKR1C3 Promoted Sorafenib Sensitivity Through Inhibiting the Phosphorylation of AKT in Hepatocellular Carcinoma
por: Zheng, Jia, et al.
Publicado: (2022)

The silencing of FNDC1 inhibits the tumorigenesis of breast cancer cells via modulation of the PI3K/Akt signaling pathway
por: Yunwen, Chen, et al.
Publicado: (2021)

Nrf2 Overexpression Decreases Vincristine Chemotherapy Sensitivity Through the PI3K-AKT Pathway in Adult B-Cell Acute Lymphoblastic Leukemia
por: Wang, Li, et al.
Publicado: (2022)

Effect of the Hypoxia Inducible Factor on Sorafenib Resistance of Hepatocellular Carcinoma
por: Zeng, Zhi, et al.
Publicado: (2021)

LncRNA HEIH Confers Cell Sorafenib Resistance in Hepatocellular Carcinoma by Regulating miR-98-5p/PI3K/AKT Pathway
por: Shen, Qian, et al.
Publicado: (2020)

Galectin-1 induces hepatocellular carcinoma EMT and sorafenib resistance by activating FAK/PI3K/AKT signaling
por: Zhang, P-F, et al.
Publicado: (2016)

Camrelizumab Plus Sorafenib Versus Sorafenib Monotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Analysis
por: Liu, Qinqin, et al.
Publicado: (2021)

CAMK1D Inhibits Glioma Through the PI3K/AKT/mTOR Signaling Pathway
por: Jin, Qianxu, et al.
Publicado: (2022)

Improving the Therapeutic Efficacy of Sorafenib for Hepatocellular Carcinoma by Repurposing Disulfiram
por: Zhang, Gong, et al.
Publicado: (2022)

Targeting PI3K/Akt/mTOR Signaling in Cancer
por: Porta, Camillo, et al.
Publicado: (2014)

Sema3d Restrained Hepatocellular Carcinoma Progression Through Inactivating Pi3k/Akt Signaling via Interaction With FLNA
por: Li, Yiming, et al.
Publicado: (2022)

BEZ235 Increases the Sensitivity of Hepatocellular Carcinoma to Sorafenib by Inhibiting PI3K/AKT/mTOR and Inducing Autophagy
por: Cao, Weiya, et al.
Publicado: (2021)

Clustering analysis and prognostic model based on PI3K/AKT-related genes in pancreatic cancer
por: Deng, Xiangying, et al.
Publicado: (2023)

Inhibition of MMP-2 Expression Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinoma by Suppressing the PI3K/AKT/mTOR Pathway
por: Tan, Wenliang, et al.
Publicado: (2017)

Emerging landscape of circFNDC3B and its role in human malignancies
por: Sun, Kai, et al.
Publicado: (2023)

Periplocymarin Induced Colorectal Cancer Cells Apoptosis Via Impairing PI3K/AKT Pathway
por: Cheng, Yi, et al.
Publicado: (2021)

The PTEN/PI3K/AKT Pathway in vivo, Cancer Mouse Models
por: Carnero, Amancio, et al.
Publicado: (2014)

Functional role of MicroRNA/PI3K/AKT axis in osteosarcoma
por: Xiang, Yubo, et al.
Publicado: (2023)

LLGL2 Increases Ca(2+) Influx and Exerts Oncogenic Activities via PI3K/AKT Signaling Pathway in Hepatocellular Carcinoma
por: Leng, Shusheng, et al.
Publicado: (2021)

Development of an Aerobic Glycolysis Index for Predicting the Sorafenib Sensitivity and Prognosis of Hepatocellular Carcinoma
por: Pan, Yu, et al.
Publicado: (2021)

Prognostic Nomogram for Sorafenib Benefit in Hepatitis B Virus-Related Hepatocellular Carcinoma After Partial Hepatectomy
por: Dong, Wei, et al.
Publicado: (2021)

The Role of Non-Coding RNAs in the Sorafenib Resistance of Hepatocellular Carcinoma
por: Hu, Xinyao, et al.
Publicado: (2021)

CK-3, A Novel Methsulfonyl Pyridine Derivative, Suppresses Hepatocellular Carcinoma Proliferation and Invasion by Blocking the PI3K/AKT/mTOR and MAPK/ERK Pathways
por: Wu, Qiong, et al.
Publicado: (2021)

SENP2 Reduces Hepatocellular Carcinoma Stemness and Improves Sorafenib Sensitivity Through Inactivating the AKT/GSK3β/CTNNB1 Pathway
por: Tang, Xiaohui, et al.
Publicado: (2021)

Hypoxia-Induced Aquaporin-3 Changes Hepatocellular Carcinoma Cell Sensitivity to Sorafenib by Activating the PI3K/Akt Signaling Pathway
por: Malale, Kija, et al.
Publicado: (2020)

Y-box binding protein 1 augments sorafenib resistance via the PI3K/Akt signaling pathway in hepatocellular carcinoma
por: Liu, Ting, et al.
Publicado: (2021)

Heterogeneity of Phosphatidylinositol-3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin Activation in Cancer: Is PI3K Isoform Specificity Important?
por: Cintas, Célia, et al.
Publicado: (2018)

FNDC3B and BPGM Are Involved in Human Papillomavirus-Mediated Carcinogenesis of Cervical Cancer
por: Zhang, Luhan, et al.
Publicado: (2021)

MicroRNA-92b augments sorafenib resistance in hepatocellular carcinoma via targeting PTEN to activate PI3K/AKT/mTOR signaling
por: Cheng, Zhouyang, et al.
Publicado: (2021)

GLUD1 suppresses renal tumorigenesis and development via inhibiting PI3K/Akt/mTOR pathway
por: Wang, Lei, et al.
Publicado: (2022)

Non-coding RNAs: Emerging Regulators of Sorafenib Resistance in Hepatocellular Carcinoma
por: Lai, Yongting, et al.
Publicado: (2019)

Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure
por: Kuo, Yuan-Hung, et al.
Publicado: (2021)

Survival and adverse events of elderly patients treated with sorafenib for hepatocellular carcinoma
por: Soria, Anna, et al.
Publicado: (2022)

YBX3 Mediates the Metastasis of Nasopharyngeal Carcinoma via PI3K/AKT Signaling
por: Fan, Xiaoqin, et al.
Publicado: (2021)

Hypoxia-Induced Aquaporin-3 Changes Hepatocellular Carcinoma Cell Sensitivity to Sorafenib by Activating the PI3K/Akt Signaling Pathway [Retraction]
Publicado: (2021)

GPRC5A Is a Negative Regulator of the Pro-Survival PI3K/Akt Signaling Pathway in Triple-Negative Breast Cancer
por: Yang, Lu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_nasd46kck1lelrorce4b9b4qds